Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis.

ABSTRACT:

Background

The Rearranged during Transfection (RET) gene represents a rare driver mutation in non-small cell lung cancer (NSCLC) occurring in only 1 %-2 % of cases, with implications in targeted carcinogenesis. Despite the significant efficacy demonstrated by immunotherapy in advanced NSCLC with wild-type driver genes, its validation in RET fusion-positive patients is yet to be established.

Objectives

This meta-analysis aims to systematically evaluate the effectiveness of immunotherapy in patients with RET fusion-positive NSCLC.

Data sources

and Methods: PubMed and Web of Science databases were systematically searched for relevant studies. Outcomes including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS)

SUBMITTER: Peng Z 

PROVIDER: S-EPMC11324980 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature